DiaSorin
Diasorin Submits Gram-Positive Bacteria Panel for FDA 510(k) Clearance
The Gram-positive blood culture assay is the firm's third panel for the detection and identification of bloodstream pathogens using the Liaison Plex instrument.
Strong Immunodiagnostics Demand Drives 6 Percent Rise in Diasorin's Q3 Revenues
The company reported on Tuesday that its revenues jumped 8 percent in North America and Europe during the third quarter but fell slightly in the rest of the world.
Diasorin Submits Gram-Negative Bacteria Panel for FDA 510(k) Clearance
The firm's Gram-negative blood culture assay is used to identify bacterial pathogens and drug resistances, with results within two hours of a Gram stain.
Diasorin Non-COVID Revenues Jump 8 Percent on Rising Immunodiagnostics, Molecular Testing Business
The firm reported gains in immunodiagnostics and molecular testing revenues in Europe and North America during the first half of 2024, offset by declines elsewhere.
Diasorin Nabs FDA De Novo Clearance for Candida Auris Assay
The firm said that the test can be used to help prevent and control the spread of the fungal pathogen, which is a common cause of hospital-acquired infections.